Xeris Biopharma's Strong Recorlev Momentum and Pipeline Opportunity

Xeris Pharmaceuticals' shares have surged 100% YoY due to strong commercial revenue growth, improved operational discipline, and positive pipeline results. The company's focus on rare disease treatments and biosimilar opportunities has contributed to its success. Recorlev's momentum is particularly notable, with sales expected to reach $500M by 2025. Xeris' pipeline also includes several late-stage candidates with the potential to further drive growth.